secwatch.observer — SEC 8-K summary
======================================

Issuer:     Natera, Inc. (NTRA)
CIK:        0001604821
Form:       8-K
Filed at:   2023-11-08T23:59:59+00:00
Accession:  0001104659-23-115735
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Natera Q3 revenue $268.3M (+27% YoY), raises FY2023 revenue and margin guidance, reduces cash burn
--------------------------------------------------------------------------------

- Revenue $268.3M, up 27% YoY; product revenue $265.2M, up 33% YoY.
- Processed ~626,000 tests (+21% YoY); oncology tests ~89,000 (+68% YoY) with 81,000 Signatera clinical units (+85%).
- Net loss improved to $109.0M ($0.95/share) from $121.5M ($1.25/share) in Q3 2022.
- Raises 2023 revenue guidance to $1.035B-$1.05B (from $1.015B-$1.035B); cash burn reduced to $260M-$280M (from $300M-$325M).
- Cash, equivalents and investments $936.6M; total debt $363.0M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1604821/000110465923115735/0001104659-23-115735-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1604821/000110465923115735/tm2329774d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-115735

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer